Evidence of simian virus 40 exposure in a colony of captive baboons  by Westfall, Landon W. et al.
Virology 377 (2008) 54–62
Contents lists available at ScienceDirect
Virology
j ourna l homepage: www.e lsev ie r.com/ locate /yv i roEvidence of simian virus 40 exposure in a colony of captive baboons
Landon W. Westfall a, Michael H. Shearer a, Cynthia A. Jumper b, Gary L. White c, James F. Papin d,
Richard Eberle e, Janet S. Butel f, Robert K. Bright a, Ronald C. Kennedy a,⁎
a Department of Microbiology and Immunology, Texas Tech University Health Sciences Center, 3601 4th Street STOP 6591, Lubbock, TX 79430, USA
b Department of Internal Medicine, Texas Tech University Health Sciences Center, 3601 4th Street STOP 9410, Lubbock, TX 79430, USA
c Division of Animal Resources University of Oklahoma Health Sciences Center, Oklahoma City, OK 73190, USA
d Department of International Laboratory of Molecular Biology for Tropical Disease Agents, University of California, Davis, CA 95616, USA
e Department of Veterinary Pathobiology, Center for Veterinary Health Sciences, Oklahoma State University, Stillwater, OK 74078, USA
f Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX 77030, USA⁎ Corresponding author. Department of Microbiology
University Health Sciences Center, 3601 4th Street, Lubb
+1 806 743 2334.
E-mail address: ronald.kennedy@ttuhsc.edu (R.C. Ke
0042-6822/$ – see front matter © 2008 Elsevier Inc. Al
doi:10.1016/j.virol.2008.03.035A B S T R A C TA R T I C L E I N F OArticle history: Simian virus 40 (SV40) is a p
Received 15 January 2008
Returned to author for revision
3 March 2008
Accepted 27 March 2008
Available online 16 May 2008
Keywords:
Simian virus 40
Simian virus large tumor antigenolyomavirus for which non-human primates are the permissive host. The baboon
(Papio spp.) is an old world monkey that is used in a variety of research investigations; however, natural
infection of SV40 among baboons has not been thoroughly examined or reported. Initially, we were
interested in determining the prevalence of SV40 infection among a captive colony of baboons based on the
presence of antibodies to SV40 large T-antigen (Tag). An overall seroprevalence rate of N50% was found after
screening sera from 142 baboons in the colony based on ELISA. Endpoint titer values for serum antibody
binding to SV40 Tag reached as high as 1280 for 5 out of 142 baboons. Peptide binding assays revealed that a
range of SV40 Tag epitopes are immunogenic in the baboon, and that individual animals differ in their
humoral immune responses to SV40 Tag based on epitope recognition. Speciﬁcity to SV40 Tag and not some
other primate polyomavirus encoded large Tag was further examined by serologic reactivity to peptide
epitopes unique to SV40 Tag. Additional serology was performed to assess SV40 Tag reactivity by Western
blot and whether antibodies were capable of neutralizing SV40 infectivity in vitro. Although antibodies with
high levels of SV40 neutralization were observed in a number of the baboons, there was a lack of correlation
between viral neutralization and antibodies to SV40 Tag. Further examination using molecular-based
diagnosis and SV40 Tag speciﬁc real-time quantitative PCR determined that some of the baboons appeared to
be exposed to SV40. DNA sequence analysis of the PCR products conﬁrmed that SV40 Tag speciﬁc sequences
were detected in baboons.
© 2008 Elsevier Inc. All rights reserved.Introduction
Simian virus 40 (SV40) is a polyomavirus known to infect a variety of
old world monkeys. Studies of natural and experimental infection with
SV40 have focused primarily on Macaca mulatta, the rhesus macaque.
Viremia usually developswithin the ﬁrst few days after inoculation into
a permissive host, followed by viral neutralizing antibody within 3–
4 weeks of infection. The virus remains latent in the kidneys of infected
animals and is often shed in the urine. A large proportion of rhesus
macaques obtained from the wild demonstrate the presence of
antibodies to SV40 large tumor antigen (Tag) (Shah, 1998).
In addition to SV40, baboons can be infected by a closely related
polyomavirus, SA12. Originally isolated in 1977, SA12 was recently
sequenced and determined to have an overall identity of 75% to SV40and Immunology, Texas Tech
ock, TX 79430-6591, USA. Fax:
nnedy).
l rights reserved.at the DNA level. Furthermore, these polyomaviruses are closely
related to the human polyomaviruses BK and JC (Cantalupo et al.,
2005). Immunologically the Tag protein in these viruses can cross
react serologically; however, DNA sequence analyses reveals discern-
able differences in the Tags sequences especially at their C-terminal
regions. It is these differences that researchers exploit via polymerase
chain reaction (PCR) to determine which type of polyomavirus is
present in a given tissue. This is extremely important when
determining the etiological signiﬁcance of polyomaviruses in the
role of multiple diseases and malignancies.
Studies have provided evidence that SV40 may play a role in a
number of human cancers, including human brain tumors, malignant
pleural mesotheliomas (MPM), osteosarcomas, pituitary tumors,
papillary thyroid carcinomas, breast, prostate and bronchopulmonary
carcinomas (Bergsagel et al., 1992; Butel and Lednicky, 1999; Carbone
et al., 1997; Garcea and Imperiale, 2003; Lednicky et al., 1995; Lowe et
al., 2007; Pass et al., 1996). Speciﬁc SV40 Tag-like sequences have been
ampliﬁed from human ependymoma, choroid plexus tumors, lym-
phomas and other hematological malignancies (Bergsagel et al., 1992;
Fig.1. Serologic proﬁle of 142 baboons for reactivity of serum antibody to SV40 Tag. Dots
represent the mean of triplicate OD values for individual animals. Lines represent cutoff
levels for positive reactivity (0.110 for adult serum diluted 1:20, 0.089 for adult serum
diluted 1:50, and 0.100 for infant serum diluted 1:20) determined by calculating the
mean of 10 negative control OD values ±3 standard deviations.
Table 1
Prevalence of SV40 Tag seroreactivity in relation to age, gender, species, and origin
Male Female Total
Age (years)
0–3 57% (8/14) 56% (18/32) 57% (26/46)
4–6 ND 60% (3/5) 60% (3/5)
7–15 67% (2/3) 53% (24/45) 54% (26/48)
N15 ND 43% (3/7) 43% (3/7)
Totals 59% (10/17) 54% (48/89) 55% (58/106)
Species
P. anubis 83% (5/6) 56% (27/48) 59% (32/54)
P. anubis/cynocephalus 50% (1/2) 67% (2/3) 60% (3/5)
P. cynocephalus 38% (3/8) 48% (12/25) 45% (15/33)
P. ursinus ND 60% (6/10) 60% (6/10)
Totals 56% (9/16) 53% (47/86) 55% (56/102)
Origin
OUHSC 54% (7/13) 62% (21/34) 60% (28/47)
Osage ND 0% (0/4) 0% (0/4)
Wild Caught 1 ND 50% (2/4) 50% (2/4)
Wild Caught 2 100% (1/1) 55% (12/22) 57% (13/23)
Wild Caught 3 ND 57% (4/7) 57% (4/7)
University of Illinois 100% (1/1) 100% (2/2) 100% (3/3)
Yerkes 50% (1/2) 47% (7/15) 47% (8/17)
Totals 59% (10/17) 55% (48/88) 55% (58/105)
Values presented as percent animals positive for anti-SV40 Tag serum antibody.
Numbers in parenthesis represent the number of positive animals out of total animals
examined for that group. Not determined (ND). Origins of animals: The OUHSC, Osage
Research Primates, Osage Beach, MO (Wild Caught 1), Charles River Biomedical
Research, TX (Wild Caught 2), Buckshire, Perkasie PA (Wild Caught 3), University of
Illinois, and Yerkes Regional Primate Research Center.
Table 2
Pedigree demonstrating SV40 Tag seroprevalence among dams, and offspring of three
male baboons
Sire Dam Offspring
1 (+) 1 (+) M (−)
2 (−) F (−)
3 (−) F (+)
4 (+) M (−)
2 (−) 5 (+) F (−)
55L.W. Westfall et al. / Virology 377 (2008) 54–62Meneses et al., 2005; Vilchez and Butel, 2007). Furthermore, SV40
enhancer region and Tag gene sequences have been identiﬁed in
pediatric brain tumors (Lednicky et al., 1995). A number of MPM
patients express SV40 in mesothelioma tissue, and antibodies and
cell-mediated immune responses to SV40 Tag have been reported
among individuals with MPM (Bright et al., 2002; Pass et al., 1996).
SV40 Tag has also been shown to bind p53 in human mesotheliomas,
further supporting the potential role of SV40 in the development of
human MPM (Carbone et al., 1997). In transgenic mice when SV40
promoter/enhancer activity is restricted to the choroid plexus, SV40
promoter/Tag transgenic mice have been reported to develop choroid
plexus tumors (Brinster et al., 1984). Additional transgenic mouse
models have utilized Tag to demonstrate tumor foci in prostate
(TRAMP), liver and the differentiation of melanocytes in skin
malignancies (Araki et al., 1991; Beermann et al., 1999; Foster et al.,
1997).
Natural infection of SV40 among baboons has been previously
described (Payton et al., 2004) although detailed molecular character-
ization and the serologic and functional proﬁle of antibodies to SV40
in baboons have not been reported. Screening for SV40 infection
among baboons is important for several reasons. First, it has beenFig. 2. Western blot proﬁles of six representative animals. Serum from baboons was
diluted 1:50 and analyzed against mKSA cell lysates as source of SV40 Tag by Western
blot. Lane (a) contains a negative control antibody. Lanes (b–d) contain serum from
animals determined to be negative for anti-SV40 Tag antibody by ELISA. Lanes (e–g)
contain serum from animals determined positive for anti-SV40 Tag antibody by ELISA.recognized that macaques infected with simian immunodeﬁciency
virus (SIV) develop cancers similar to those found in humans (Horvath
et al., 1992; Hurley et al., 1997; Ilyinskii et al., 1992; Lednicky et al.,
1998); suggesting that immunocompromised baboons may also6 (−) M (+)
7 (−) M (−)
8 (−) M (−)
9 (+) F (+)
3 (+) 10 (−) F (−)
11 (−) M (+)
12 (−) F (−)
13 (+) F (+)
14 (−) F (+)
15 (−) M (+)
16 (+) F (+)
F (−)
17 (−) M (−)
18 (+) F (−)
19 (−) F (+)
20 (−) M (+)
21 (+) F (+)
22 (−) F (−)
F (−)
23 (−) M (+)
24 (+) M (+)
F (+)
25 (−) F (−)
Pedigree demonstrating SV40 Tag seroprevalence among dams and offspring of three
male baboons. A (+) denotes seropositive animals and a (−) seronegative animals as
determined by ELISA. M and F represent male and female offspring respectively.
Table 3
Endpoint titers of anti-SV40 Tag response in baboons
Number of animals having endpoint titers of
b20 20 40 80 160 320 640 1280
SV40 Tag 66 23 12 7 9 11 9 5
Values are listed as the number of animals having the endpoint titer indicated. A total of
142 animals were examined.
56 L.W. Westfall et al. / Virology 377 (2008) 54–62develop such cancers if infected with SV40. Due to the immunologic
similarity between baboons and humans (Kennedy et al., 1997;
Shearer et al., 1999) it is possible that this animal may provide a
useful model for studies on the immunologic response to SV40-
induced human cancers. Second, the presence of SV40 in baboons
suggests a possible risk of non-human primate to human transmis-
sion, emphasizing a need for viral screening prior should one consider
xenotransplantation using non-human primate donors (Allan, 1996;
Allan et al., 1998) and/or associated exposure risk to animal care takers
and management personnel. Baboons are also employed in numerous
research studies and it is important to ensure that infection with this
virus does not inﬂuence the interpretation of ﬁndings obtained from
such studies. Finally, the presence of SV40 within a captive breeding
colony may impact issues related to overall colony management.
Methods for the identiﬁcation of seropositive animals and
serologic reactivity to SV40 Tag are crucial to understanding the
prevalence of primate infection with SV40 and other closely related
polyomaviruses. A detailed characterization is important for contin-
ued research in this primate model and may provide insight into the
pathogenic consequences of SV40 infection in a permissive host. In
this study, a captive colony of baboons was examined for exposure toFig. 3. The binding curves of serum from four representative baboons binding to SV40
Tag (Panel A) and BSA (panel B). Each point represents the mean of triplicate
measurements. The individual values obtained did not exceed 5% of the mean value that
is plotted.SV40. Our results provide serologic and molecular evidence of SV40
exposure within this colony of baboons. These ﬁndings emphasize the
importance of screening donors to ensure that SV40 infection does not
inﬂuence results obtained from studies using the baboon as an animal
model for biomedical research that may be relevant for predicting
certain human immune responses and health conditions.
Results
In order to determine the percentage of baboons infected with
SV40 in our colony, we initially screened serum samples from 142
baboons (89 infants and 53 adults) at a 1:20 dilution for antibodies to
SV40 Tag by ELISA. Overall, 57% (51 infants and 30 adults) demon-
strated antibodies reactive to SV40 Tag. Adult serumwas subsequently
examined at a 1:50 dilution for which 20 adults remained positive for
anti-SV40 Tag antibodies. The overall seroprevalence of this colony is
greater than 50%. These serologic proﬁles are summarized in Fig. 1.
To conﬁrm seroreactivity with SV40 Tag, Western blot analysis was
performed using a murine SV40-transformed kidney ﬁbroblast cell
(mKSA) lysate as the source of SV40 Tag. Sera from representative
seropositive and seronegative baboons were examined for the ability
to bind SV40 Tag derived from the mKSA cell lysate. Seropositive
samples displayed a band at approximately 97 kDa (Fig. 2, lanes e–g),
while seronegative samples failed to exhibit such a band (Fig. 2, lanes
b–d). A murine mammary adenocarcinoma cell line, designated 4T1,
that is negative for SV40 Tag (Lewis et al., 2005) was used to obtain a
control cell lysate. Western blot analysis using the 4T1 cell lysate and
representative seropositive baboon sera demonstrated no reactivity
(data not shown). Western blot analysis thus conﬁrmed the presence
of anti-SV40 Tag antibody in baboon sera determined positive by
ELISA.
The seroprevalence rates of over 100 animals were additionally
analyzed with regard to age, species, origin, and gender (Table 1). The
results demonstrate that the frequency of SV40 infection remains
relatively constant with age of the animal (57% for 0–3 years and 43%
for N15 years). Seroprevalence rates between species were also similarFig. 4. Representative inhibition curves of serum from ﬁve seropositive baboons using
soluble SV40 Tag (Panel A) or BSA (Panel B) as inhibitor of serum antibody binding to
solid phase SV40 Tag. Each point represents the mean of triplicate measurements.
Fig. 5. Alignment of the SV40 Tag unique 690 peptide against SA12 Tag.
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60% in both P. ursinus and P. anubis/P. cynocephalus hybrids). Since the
baboons housed within the colony were obtained from a variety of
locations in order to establish this breeding colony and increase the
colony size; it was of interest to determine whether differences in
seroprevalence rates might relate to baboon origin. Seroprevalence
rates ranged from a low rate of 0% in baboons obtained from Osage
Research Primate Center to a high rate of 100% in baboons obtained
from the University of Illinois. These data indicate that age and species
have no correlation with state of infection by SV40 within this colony.
The origin of the animal may play a role in the rate of infection by
SV40, although this could result from the small sample size of baboons
obtained from the Osage Primate Research Center (n=4, 0%) and the
University of Illinois (n=3, 100%). This possible correlation is
supported, however, in the larger samplings, such as the University
of Oklahoma Health Sciences Center (OUHSC) breeding colony and
Wild Caught, where the overall prevalence was greater than 50%. No
correlation between gender and SV40 infection was observed
throughout the course of analysis.
Many baboons within our colony were born in the colony and the
parents of these offspring are known. It was of interest to us to
examine whether the vertical or sexual transmission of SV40 occurs
within the colony. We examined the serology of sires, dams and
offspring from several pedigrees. A pedigree of three representative
sires and a total of 28 offspring from 25 dams are shown in Table 2.
There appears to be no correlation between parental lineage and SV40
infection of offspring. Forty-eight percent of offspring possess the
same serology as the mother and 54% the same serology as the father.
In addition, no correlation is found between state of sire and state of
dam (40% of sires and dams had the same serology). Approximately
50% of the baboons housed within each gang cage were serologically
positive for SV40 infection (data not shown). These results suggest
that transmission of the SV40 within this colony is through some form
of direct or indirect contact and does not appear to be transmitted
speciﬁcally from the mother during birth or through sexual contact.
To quantify the level of anti-SV40 Tag antibody present in the
serum of positive baboons, endpoint titers were determined using
ELISA. Endpoint titer values reached as high as 1280 for 5 out of 142
baboons (Table 3). The majority of seropositive baboons had anTable 4
Reactivity of baboon serum to SV40 Tag synthetic peptides
Peptide number
660 472 690
1:50 1:200 1:50 1:200 1:50 1:200
2 0.030 0.024 0.057 0.000 0.063 0.044
37 0.045 0.044 0.073 0.009 0.062 0.071
69 0.061 0.045 0.066 0.002 0.066 0.058
72 0.052 0.055 0.073 0.007 0.056 0.066
75 1.037 1.522 0.187 0.063 0.116 0.028
9 0.037 0.020 0.108 0.002 0.073 0.038
32 0.042 0.036 0.075 0.001 0.061 0.062
39 0.063 0.043 0.064 0.000 0.057 0.070
10 0.065 0.054 0.058 0.000 0.070 0.058
70 0.063 0.049 0.075 0.009 0.078 0.073
Tag 0.468 0.198 0.544 0.203 0.599 0.301
BSA 0.010 0.008 0.046 0.001 0.033 0.034
Values represent the mean of triplicate O.D. values obtained for each group. Serum reactivity
this study, designated by a serum sample number. SV40 Tag was applied on the solid phase
different seropositive animals. BSA was applied in place of peptide as a negative control. Vaendpoint titer of 20 (23/142 baboons). In order to conﬁrm the SV40
Tag binding speciﬁcity of the serum antibody, binding curves were
constructed by ELISA using four fold dilutions of sera ranging from
1:4–1:4096. Binding curves of serum to bovine serum albumin (BSA)
were examined as a non-speciﬁc antigen control. Representative
binding curves to SV40 Tag and BSA for four baboons (one high
positive, one low positive and two negative) are shown in Fig. 3.
Optical density readings ranged from 0.071 to 0.716 for the baboon
with the highest endpoint titer and from 0.059 to 0.151 for the baboon
that was seronegative. Binding to the BSA negative control antigen
ranged from a low reading of 0.085 to a high reading of 0.196 for the
four baboon sera that were examined. The binding curves observed for
SV40 Tag and BSA suggest that the binding is indeed speciﬁc for SV40
Tag. This data also conﬁrms the endpoint titers determined from the
previous ELISA (Table 1).
To further conﬁrm the speciﬁcity of binding for SV40 Tag,
baculovirus-derived recombinant (r) SV40 Tag was examined for its
ability to inhibit the binding of baboon serum antibody to SV40 Tag in
a solid phase inhibition assay. Binding of anti-SV40 Tag-positive serum
to solid phase SV40 Tag increased with decreasing concentrations of
inhibitor SV40 Tag. At 10 µg/ml of SV40 Tag, OD readings ranged from
0 to 0.098 and represented almost complete inhibition. At the lowest
concentration (0.001 µg/ml) of SV40 Tag, OD readings increased to a
range between 0.155 and 0.632 and represented little to no inhibition
(Fig. 4A). When BSA was used as the inhibitor, binding of anti-SV40
Tag-positive serum did not vary with decreasing inhibitor concentra-
tion. At the highest BSA inhibitor concentration (10 µg/ml BSA as an
inhibitor), little to no inhibitionwas observed (OD values ranged from
0.084 to 0.515). Similarly, little to no inhibition was observed with
0.001 µg/ml of BSA as an inhibitor (Fig. 4B). The patterns observed
with the inhibition assays further conﬁrm that the binding to SV40 Tag
is speciﬁc.
To examine which epitopes were involved in the antibody
response to SV40 Tag, the baboon anti-SV40 Tag-positive sera were
examined for their ability to bind a variety of synthetic peptides
corresponding to six predicted B-cell epitopes spanning SV40 Tag.
These peptides have been previously examined in murine systems in
which serum from BALB/c mice and CB6/F1 mice immunized with
rSV40 Tag recognized peptides 690 and 660, respectively (Bright et al.,
1994a; Bright et al., 1994c). These peptides correspond to two distinct
linear epitopes associated with the carboxy-terminal region of SV40
Tag with the carboxyl-terminal epitope 690 and its associated amino
acid sequence being unique to SV40 Tag. We conducted a BLAST® and
BLAST2® analyses of the 690 synthetic peptide. Based on the amino
acid sequence, the 690 peptide was not similar/identical to any other121 36 632
1:50 1:200 1:50 1:200 1:50 1:200
0.072 0.053 0.039 0.000 0.062 0.004
0.441 0.063 0.140 0.001 0.097 0.013
0.065 0.037 0.056 0.008 0.087 0.004
0.079 0.057 0.064 0.006 0.074 0.001
0.150 0.092 0.137 0.016 0.183 0.076
0.110 0.073 0.082 0.000 0.128 0.037
0.058 0.065 0.105 0.018 0.087 0.025
0.047 0.061 0.082 0.006 0.076 0.023
0.057 0.048 0.059 0.015 0.050 0.010
0.074 0.056 0.098 0.012 0.101 0.015
0.550 0.269 0.336 0.224 0.416 0.287
0.037 0.052 0.028 0.000 0.086 0.005
was examined for dilutions of 1:50 and 1:200. Ten seropositive individuals were used in
in place of peptide as a positive control. Serum reactive with SV40 Tag was from three
lues in bold are those considered positive for peptide binding.
Table 5
Baboon colony SV40 neutralizing titers
Number Designation Neutralizing titer
1 1098 10,000
2 2224 10,000
3 1698 20,000
4 1497 0
5 57288 0
6 497 0
7 698 0
8 498 500
9 1298 0
10 798 0
11 1397 0
12 869 100
13 1496 0
14 942 150
15 958 0
16 715 0
17 9604 0
18 920 0
19 2602030 0
20 1016 0
21 57291 10
22 954 5000
23 57295 0
24 181 0
25 124269 0
26 826 20
27 748 50,000
28 1296 500
29 57310 0
30 785 0
31 1076 0
32 1498 0
33 1198 10
34 3397 10
35 1697 5000
36 2597 0
37 948 20
38 57308 50
39 789 200
40 124270 0
41 1730 0
42 89092 20
43 885 500
44 CR1H 0
45 88045 0
46 CR9H 100
47 86287 20
48 89398 0
49 90071 0
50 86019 500
51 786 500
52 87127 500
53 91157 500
54 CR714 20,000
55 376 500
56 85241 5000
57 84189 0
58 8606 20
59 CR283 50
60 89283 0
61 124273 50,000
62 79114 20
63 91023 500
64 CR963 10,000
65 53104 0
66 1197 20,000
67 484 5000
68 898 15,000
69 9605 50
70 2183 0
71 2437936 50,000
72 59229 0
73 1713 0
74 78131 0
75 2197 2000
76 1215 0
77 298 20,000
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to SA12 Tag, we discovered that these sequences are 58% identical
(Fig. 5). Based on the published literature regarding the recognition of
linear peptide epitopes there is not enough identity to SA12 to cause a
cross reaction with the 690 peptide (Attanasio et al., 1993). Serum
from 10 baboons with anti-SV40 Tag endpoint titers ranging from 20–
1280 was diluted at 1:50 and at 1:200 and examined for the ability to
bind the six synthetic peptides by ELISA. Recombinant SV40 Tag and
BSA were used as positive and negative controls, respectively.
Interestingly, serum from animal #75 bound all six peptides at a
1:50 dilution, with strongest binding being observed to peptide 660 at
both dilutions tested (Table 4). This was the only animal whose serum
bound the two peptides (690 and 660) that are associated with
carboxy-terminal epitopes. Serum from animal #9 weakly bound
peptides corresponding to the central region of SV40 Tag (peptide 472)
along with epitopes associated with the amino (peptide 121) and
carboxyl (peptide 632) terminal regions. Serum from animal #37
weakly bound peptides corresponding to the amino-terminus of SV40
Tag (peptides 36 and 121). Peptides 36 and 121 were reacted the most
frequently (3/10 baboons) at a 1:50 dilution. Six out of ten animals
positive for anti-SV40 Tag serum antibody did not exhibit binding to
any of the peptides examined.
The ability of the polyclonal anti-SV40 Tag serum of baboon #75 to
speciﬁcally bind to SV40 Tag peptides that deﬁne distinct epitopes on
the carboxyl-terminus of SV40 Tag implicates the potential immuno-
dominant nature of this region of SV40 Tag in animals other than
inbred mice. However, the wide range of epitopes recognized by the
serum from other seropositive baboons within this colony reﬂects the
wide variety of immune responses elicited by individuals within an
outbred population. Alternatively, the lower antibody titer to SV40 Tag
induced by viral infectionmay also contribute to the low percentage of
baboons recognizing these six linear epitopes.
To further evaluate exposure to SV40 in this colony, we performed
a viral neutralization assay on 78 selected baboon sera that were
positive or negative for antibodies to SV40 Tag by ELISA (Table 5).
Neutralization titers (deﬁned as N50% reduction in SV40 plaque
formation) ranged from 1:10 to 1:50,000 in 42 of the 78 (53%) sera
samples were examined. This assay detects functional antibodies to
the viral structural proteins, such as VP1, that are capable of
neutralizing viral infectivity in vitro. Although the percentage of
samples that exhibited neutralizing antibodies was similar to the
overall ELISA data, there was no correlation between neutralization
and the anti-SV40 Tag ELISA (data not shown). This suggests that
exposure to other SV40-like polyomaviruses may also have occurred
in the baboon colony.
To determine the rate of ongoing infection as opposed to past
exposure, we determined cell-associated SV40 viral load in baboonFig. 6. Real-time quantitative PCR for 43 of the animals used in the serology studies.
Depicted is the frequency of positive animals for SV40 and a housekeeping gene-
chymase.
Fig. 7. (A) Representative real-time PCR demonstrating the 130 bp SV40 Tag product generated by the SV40 Tag speciﬁc real-time PCR primers from the DNA isolated from baboon
PBMCs. Individual PCR reactions were visualized on ethidium bromide stained 3% agarose. Lanes; a) Low molecular DNA ladder, b) No template control, c) Plasmid containing the
intact SV40 Tag DNA sequence, d) SV40 speciﬁc primers PCRwith baboon PBMCDNA as template, e) SA12 speciﬁc primers PCRwith baboon PBMCDNA as template. (B) DNA sequence
determination of the 130 bp SV40 Tag real-time PCR product. SV40 Tag PCR product from A compared to SV40 sequence from Genbank accession number DQ660375. Baboon DNA
amplicon aligned to SV40 Tag sequence with 100% identity.
59L.W. Westfall et al. / Virology 377 (2008) 54–62peripheral mononuclear cells (PBMC) by real-time quantitative PCR
(qRT-PCR). Only animals which ampliﬁed signiﬁcant product in two
out of two repeat reactions were considered positive. A one-time
sampling of the colony yielded a viral prevalence of 23% (n=46
animals) (Fig. 6). Baboon chymase was used as a positive control for
the real-time PCR. A representative SV40 Tag speciﬁc real-time PCR is
shown in Fig. 7A. In addition, we sought to determine whether the
baboon colony was infected with a previously described non-human
primate polyomavirus designated SA12. SA12 contains a high degree
of sequence homology when compared to SV40. Using PCR primers
speciﬁcally designed to amplify only SA12 DNA, we examined the
same number of baboons for the presence of SA12 DNA. Our results
indicate that none of the tested baboons was carrying SA12 DNA in
their PBMCs (data not shown; Fig. 7A). To further validate the
assertion that SV40 alone had infected these animals, we sequenced
the PCR product generated from the qRT-PCR. The sequencing results
conﬁrmed with 100% identity that the ampliﬁed PCR product was
solely from SV40 Tag and contained no identity to any other
polyomavirus (Fig. 7B). Taken as a whole, these data support a
relatively high rate of ongoing SV40 infection in the baboon colony.
Discussion
Natural infection of baboons with SV40 has not been thoroughly
examined and the antibody response to SV40 Tag in baboons has not
been reported previously. In this study, we examined the seroreactiv-
ity of 142 baboons to SV40 Tag in order to determine an overall
estimate of SV40 infection for this colony. Based on both ELISA and
Western blot analysis, our results indicate that more than 50% of our
captive baboon population has been infected with SV40. The
proportion of seropositive infants is similar to that of the adults
examined. Age, gender, and species did not appear to correlate with
incidence of SV40 infection. However, the origin of the baboons prior
to housingwithin the colonymight be associatedwith infection, as the
percent of seropositive animals varied with origin. Baboons werepurchased from a variety of sources in order to increase the breeding
colony size and production and improve fecundity and hybrid vigor.
One hundred percent of baboons obtained from the University of
Illinois were seropositive, while none of the baboons obtained from
Osage Research Primates was seropositive. This could also be the
result of the small sample size utilized from these two sources.
Baboons obtained from all other origins demonstrated approximately
50% incidence of SV40 infection. The overall seroprevalence of this
colony was determined to be greater than 50%, regardless of baboon
gender, age or species. A prevalence of approximately 25% was
determined by qRT-PCR, suggesting a continued persistent infection
within the colony. Since there was no correlation between serology of
parents and offspring or between parents, it appears that SV40 is not
transmitted congenitally or sexually within this baboon colony. A
previous study in rhesus macaques provided indirect evidence that
maternal-infant transmission of SV40 may have occurred in one
animal (Lednicky et al., 1998). Within this colony of baboons, the virus
is most likely transmitted through direct or indirect contact, perhaps
from the shedding of virus in the urine of infected animals or as the
result of direct social interactions among animals in the colony.
To further examine the serology of these baboons, endpoint titers
were determined using ELISA. Endpoint titers as high as 1280 were
observed, though the majority of seropositive baboons were deter-
mined to have endpoint titers of 20. This value served as the minimal
endpoint titer considered positive for SV40 Tag reactivity. Binding
curves revealed speciﬁc binding for SV40 Tag. SV40 Tag binding
speciﬁcity of baboon serum was conﬁrmed using inhibition assays, in
which binding of baboon sera to SV40 Tag was inhibited by various
concentrations of SV40 Tag. A control antigen did not inhibit binding
when incubated with positive serum prior to SV40 Tag exposure on
the solid phase.
In order to determine epitopes involved in the antibody response
to SV40 Tag, anti-SV40 Tag-positive baboon sera were examined for
their ability to bind a variety of synthetic peptides corresponding to
six predicted B-cell epitopes spanning SV40 Tag. The ability of the
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peptide deﬁning epitopes on the carboxyl-terminus of SV40 Tag
supports the potential immunodominant nature of this region of SV40
Tag in this animal. Additionally, the recognition of a unique SV40 Tag
carboxyl-terminus epitope, located to the 690 peptide, by this serum
indicates that infection in this animal maybe restricted to SV40 alone.
However, a wide range of epitopes were recognized by the sera from
other seropositive baboons. This may be explained by the variability in
immune responses often observed among outbred populations. The
failure of the sera from some strongly seropositive animals to bind any
of the six synthetic peptides suggests that the predominant antibody
response to SV40 Tag in these baboons may recognize only
conformational epitopes or epitopes not represented by the synthetic
peptides used in this study. This was previously reported for C57BL/6
mice immunized with rSV40 Tag (Bright et al., 1994c). From these
assays it appears that carboxyl-terminal epitopes of SV40 Tag exhibit
the strongest reactivity, although a wide variety of epitopes may be
immunogenic in the baboon. This observation may be dependent on
the individual, and many of these epitopes may not be represented by
the peptides used in this study.
Due to the immunologic similarity between baboons and humans,
the baboon provides an excellent tool for the study of the human
immune response to some infectious agents (reviewed in Kennedy
et al., 1997). It has been reported that, immunocompromised rhesus
macaques develop spontaneous tumors similar to those associated
with SV40 in humans (Horvath et al., 1992; Hurley et al., 1997; Ilyinskii
et al., 1992; Lednicky et al., 1998). Additionally, serologic evaluation of
HIV infected and uninfected humans has indicated infection with
SV40 (Jafar et al., 1998). Further examination of baboons infected with
SV40 may provide invaluable information pertaining to the develop-
ment of SV40-related tumors and the immune response to SV40 in
humans.
SV40 infection at the level of seroprevalence observed in this
colony suggests a possible risk of non-human primate to human
transmission. This might be important when considering appropriate
infection control measures and potential exposure to animal care
personnel. Alternatively, xenotransplantation procedures could likely
result in deleterious effects if virus is present in the donor animal.
Indeed, this concern has also been expressed for other endogenous
infectious agents found in non-human primates and xenotransplanta-
tion using non-human primates as a donor source (Allan, 1996; Allan
et al., 1998). The results of this study highlight the need for proper
screening of primates in general.
One issue with the role of SV40 in human tumors is whether
individuals are infected with SV40 or with a closely related human
polyomavirus, such as BK or JC virus. The Tags from these three
polyomaviruses are closely related and can cross react serologically
(reviewed in Butel and Lednicky, 1999). However, SV40 Tag sequences
have been identiﬁed in a variety of human tumors, and recently, SV40
DNA sequences have been identiﬁed and provide a molecular basis for
the infection of children by SV40 (Butel et al., 1999). A closely related
polyomavirus has been isolated from Papio ursinus, chacma baboons
(Valis et al., 1977). This polyomavirus, designated SA12, was
characterized morphologically and serologically and found to be
distinct from SV40. Although the Tags from SV40 and SA12 were
reciprocally cross-reactive, their DNA sequences for Tag have subtle
differences, particularly in the C-terminus of the proteins (Cantalupo
et al., 2005). To test the possibility that our baboon colony was
infected with SA12 or another closely related polyomavirus, we
employed a SV40 plaque reduction assay to demonstrate the observed
serologic cross-reactivity to SV40 Tag. The neutralizing titers from
seropositive individuals ranged from 1:10 to 1:50,000; however, there
was a complete lack of correlation between neutralization and the
SV40 Tag ELISA. Since SV40 Tag represents an early encoded viral
protein and is not associated with the viral capsid, antibody response
to SV40 Tag may underestimate the total seroprevalence whencompared to antibodies to the structural proteins that comprise the
virion. Therefore, the neutralization assays, which measured a
functional antibody response to the viral structural proteins asso-
ciated with the capsid, did not rule out the potential for exposure to
other SV40-like polyomaviruses, such as SA12. The only data that was
able to conﬁrm exposure to SV40 was from an ELISA using a unique
SV40 Tag peptide (designated 690). To determine the peptide
speciﬁcity we compared and aligned the amino acids of the 690
peptide from SV40 Tag to SA12 Tag. Our analysis indicates that the 690
peptide is not signiﬁcantly identical to SA12 Tag or any other known
polyomavirus. Furthermore, not more than 4 amino acids overlap at a
time indicated and this is not a sufﬁcient number of identical amino
acids necessary to deﬁne a minimal linear epitope (Attanasio et al.,
1993).
In an attempt to conﬁrm exposure to SV40, we performed
molecular-based diagnoses employing SV40 Tag sequence speciﬁc
primers, qRT-PCR and DNA sequencing (Whitby et al., 2003). Data
from the sequencing of the PCR products conﬁrmed that the Tag
sequence ampliﬁed was from SV40 alone. Furthermore, no SA12 Tag
sequence was detected in any of the baboons tested. The combination
of these data supports our contention that SV40 exposure had
occurred in this captive baboon colony.
Previous studies have also described the transmission of SV40 in a
baboon breeding colony by serological evaluation (Payton et al., 2004).
In this study the authors examined transmission of SV40 by ELISA that
utilized a viral infected whole cell lysate as the source of the antigen.
This ELISA recognizes predominantly SV40 structural proteins and
would not appear to contain appreciable amounts of SV40 Tag. It was
not clear from this previous study that antibodies to SV40 Tag were
detected and the speciﬁc nature of the anti-viral immune response is
not known. The serological evaluation described in our study included
an SV40 Tag speciﬁc ELISA and Western blot to assess antibodies to
SV40 Tag and viral neutralization assays to assess antibodies to
structural viral proteins that mediated functional activities during
infection.
The resulting data offer an insight into the needs of colony man-
agement, aswell as somegeneral informationon the overall frequencyof
SV40 infection among baboons. Themethods for SV40 viral screening of
the baboon colony described herein are not to be considered diagnostic,
but are simply used to indicate past SV40 infection as represented by the
presence of antibody to SV40 Tag. Investigations such as this assist in the
maintenance of healthy non-human primate colonies and in the
continued use of non-human primates for research in assessing human
immune response and viral infections. These studiesmay also be helpful
in terms of animal selection for use in non-human primate models for
human cancers.
Materials and methods
Animals
All baboons in this study were from the colony at the OUHSC. The
OUHSC animal care program is AAALAC accredited. Baboons were
housed in breeding groups (troops) composed of four to eight sexually
mature adults (one male and three to seven females, respectively, all
over 4 years of age) plus infants (up to 6 months). Juveniles were
removed from the breeding troops at approximately 6 months of age
andwere transferred to either single or group cages. The origins of the
baboons that constitute the OUHSC colony include those from the
breeding colony and those purchased from other sources that breed or
maintain baboons.
Serum collection
Blood samples were drawn from animals at the time of birth and/
or during the semiannual TB testing. Animals were sedated with
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ture. Serum was separated from clotted blood and samples were
stored at −20 °C before testing for antibodies to SV40 Tag. PBMCswere
also obtained from EDTA treated blood and isolated by sedimentation
gradients as previously described (Benton et al., 1998). Aliquots of
PBMC were snap frozen and stored at −80 °C before testing.
Elisa
SV40 Tag speciﬁcity, endpoint titers, and binding curves of baboon
sera were examined by indirect ELISA. Brieﬂy, individual wells of 96-
well microtiter plates were coated in triplicate with 200 ng of puriﬁed
rSV40 Tag (Bright et al., 1994b) or BSA in borate buffered saline (BBS).
Non-speciﬁc binding was blocked by addition of 5% normal goat
serum (NGS) in BBS after coating. Plates were washed with BBS
supplemented with 0.05% Tween-20 (BBS-T) prior to the addition of
baboon serum diluted in BBS. Plates were washed again before the
addition of horseradish peroxidase (HRP)-labeled goat anti-human
IgG at a dilution of 1:1000 in NGS. After incubation, plates were
washed and 100μl of 2,2′-azino-bis(3-ethylbenzthiazoline-6-sulfonic
acid) substrate with 0.01% hydrogen peroxide was added. The
enzyme-substrate reaction was terminated by the addition of 100 μl
of 10% sodium dodecyl sulfate (SDS). Plates were read in an automated
ELISA plate reader and the optical density (OD) at 410 nm was
determined. The OD value at 410 nm, determined to be approximately
three times that obtained for a 1:10 dilution of negative sera, was
established as the cutoff for positive antibody reactivity and
determination of the antibody endpoint titer (Warren et al., 1991).
Positive serologic reactivity of various dilutions of sera for SV40 Tag
was also determined as exceeding the mean OD of ten negative
control samples ±3 standard deviations. Anti-SV40 Tag antibodies
failed to bind normal goat serum and a control baculovirus-derived
recombinant viral antigen hepatitis B surface antigen in these assays
(data not shown). A modiﬁcation of the ELISA has been previously
used to detect serum antibodies to SV40 Tag inmurine systems (Bright
et al., 1993, 1994a,b,c).
Western blot analysis
Murine SV40-transformed kidney ﬁbroblasts (mKSA) were used as
a source of SV40 Tag for Western blot analysis. A murine mammary
adenocarcinoma cell line, designated as 4T1 that was negative for
SV40, was used as a control (Lewis et al., 2005). Cells were disrupted in
lysis buffer composed of 50 mM Tris–HCl pH 7.2, 150 mM NaCl, 1%
Triton X-100, 1% deoxycholate, and 0.1% SDS. The lysates were diluted
in denaturing electrophoresis sample buffer, and boiled for 5 min.
Proteins were separated on a discontinuous 12.5% polyacrylamide-
SDS gel. Following electrophoresis, the proteins were transferred to
0.45μm nitrocellulose for 16 h, blocked with 3% BSA-V in phosphate
buffered saline (PBS) at 37 C for 1 h, and cut into 0.5 cm strips. The
strips were reacted with a 1:50 dilution of serum in PBS+0.2% Tween-
20 and 1% BSA, followed by biotinylated goat anti-human IgG, and
streptavidin-HRP. Blots were visualized using diaminobenzidine
substrate. A 97 kDa band was identiﬁed as SV40 Tag using a murine
monoclonal antibody to SV40 Tag designated as PAb 405. These
methods are described elsewhere (Bright et al., 1993, 1994a,b,c).
Inhibition assays
SV40 Tag speciﬁcity of baboon serum samples was further
conﬁrmed using inhibition assays. Brieﬂy, individual wells of 96-
well microtiter plates were coated in triplicate with 200 ng of puriﬁed
rSV40 Tag in BBS. Non-speciﬁc binding was blocked by addition of 5%
NGS in BBS after coating. Serum samples diluted at 1:50 in BBS were
incubated with 10, 1, 0.1, 0.01, and 0.001 µg of either rSV40 Tag or BSA
overnight at 4 °C. Plates were washed as described above prior to theaddition of baboon serum/rSV40 Tag or BSAmixtures. After incubation
at 37 °C, plates were washed and HRP-labeled goat anti-human IgG
was added at a dilution of 1:1000 in NGS. After incubation, plateswere
washed, substrate was added, reaction was terminated, and plates
were read as described above. This data is expressed as OD at 410 nm
versus concentration of inhibition.
Peptide binding assays
To examine the ability of anti-SV40 Tag-positive baboon sera to
recognize SV40 Tag epitopes deﬁned by synthetic peptides, an ELISA
similar to that described above was utilized. Synthetic peptides were
derived from the amino acid sequence of SV40 Tag based on the
known nucleic acid sequence. Peptides 36, 121, 472, 632, 660, and 690
correspond to amino acid numbers 36–56, 121–141, 472–490, 632–
652, 660–679, and 690–708 of SV40 Tag, respectively. The synthesis
and puriﬁcation of these peptides have been described in detail
elsewhere (Bright et al., 1994a,c). Brieﬂy, individual wells of 96-well
microtiter plates were coated in triplicate with 250 ng of each
individual synthetic peptide, rSV40 Tag, or BSA in BBS. Non-speciﬁc
binding was blocked and plates were washed prior to the addition of
baboon serum diluted 1:50 and 1:200 in BBS. Plates were washed
again before the addition of HRP-labeled goat anti-human IgG at a
dilution of 1:1000 in NGS. After incubation, plates were washed,
substrate was added, reactionwas terminated, and plates were read as
described above.
SV40 neutralization assay
A plaque reduction assay was used to detect speciﬁc SV40
serological reactivity. SV40 plaque assays were performed as pre-
viously described (Jafar et al., 1998). Brieﬂy, heat-inactivated serum
samples were diluted and mixed with SV40 (50 to 100 pfu/ml). Each
assay included virus and serum controls. All samples were incubated
prior to infection of monkey kidney (TC-7) monolayers. Monolayers
were overlaid with agar and after 11 days stained for plaques with
neutral red. Plaques were counted on day 15. Each sample was tested
in triplicate. Endpoint neutralization titers were those dilutions that
reduced the number of plaques by N50% compared to control samples.
Real-time PCR for SV40
DNA was puriﬁed from PBMC using Quiagen DNAeasy following
the manufacturer's instructions and subjected to qRT-PCR using SYBR
green-based detection (Fakhari and Dittmer, 2002; Shi et al., 1999).
The SV40 Tag speciﬁc real-time PCR primers used in this study were
previously published by Whitby et al. (2003). Positive and negative
controls consisted of a standard cloning vector with and without the
complete sequence of the SV40 Tag (~2127 bp) (Fakhari and Dittmer,
2002). The gene encoding a chymase was used as the internal control
with a 100% detection rate in all baboons. Ct values were considered
positive when the values were at least 5 cycles ahead of the no
template control. 5 Ct values represent ~1.5 log difference (3.3 Ct per 1
log). For visualization of SV40 Tag real-time PCR products 1 μg of total
DNA from a baboon's PBMC was used as a template. A plasmid
containing the intact SV40 Tag sequence (pCMV-Tag) was used as a
positive control (Lowe et al., 2005). The SA12 Tag speciﬁc real-time
primers used in this studywere previously published (Cantalupo et al.,
2005).
Sequencing of PCR products
The 130 bp PCR ampliﬁed product from the C-terminus of the large
T-antigen of SV40 was sequenced using the TOPO TA Cloning Kit for
sequencing purchased from Invitrogen. Brieﬂy, the high copy plasmid
pCR® 4-TOPO contains the pUC origin of replication with the Plac
62 L.W. Westfall et al. / Virology 377 (2008) 54–62promoter for the transcription of lacZα fused with ccbdB, a counter-
selectable gene used for screening potential clones in E. coli. In
addition, the vector contains four sites for sequencing primers (M13
forward and reverse, T3 and T7) to conﬁrm successful cloning. The
TOPO® cloning site is located −70 bp of the lacZα initiation codon.
Cloning reactions were conducted according to manufacturer's
speciﬁcations. Potential clones were analyzed using the restriction
enzyme Eco RI (New England Biomedical) and sequenced using the
T3/T7 primer set. Sequencing was conducted at the Texas Tech
University Biotechnology Core Facility located in Lubbock, Texas using
the dideoxy termination sequencing method.
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